Navigation Links
Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
Date:4/28/2008

SHELTON, Conn., April 28 /PRNewswire/ -- Cara Therapeutics, Inc. today announced that it has initiated a Phase 1 clinical trial of its long-acting peripheral kappa opioid receptor agonist, CR845. The Phase 1a single-center clinical trial will evaluate the safety, tolerability, pharmacokinetic profile, and pharmacological activity of CR845 in a double-blind, randomized, placebo-controlled, single escalating intravenous dose study in 58 healthy male and female volunteers.

The company is also developing oral and subcutaneous formulations of CR845.

About CR845

In preclinical studies, CR845 was highly selective for the peripheral kappa opioid receptor. Animal studies indicate that CR845 is effective in treating pain of inflammatory, neuropathic and visceral origin and exhibits analgesic efficacy for up to 18 hours after a single dose. Analgesic activity was seen after intravenous, subcutaneous, or oral administration. Unlike currently marketed opioids, CR845 did not inhibit intestinal transit (ileus) or elicit signs of addiction in animal models. Preclinical studies also indicate that CR845 possesses anti-itch activity.

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara's current pipeline includes near-term clinical drug candidates identified as mechanistically distinct, peripherally-acting analgesics.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of CR845 and about Cara's strategy, technologies, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may dif
'/>"/>

SOURCE Cara Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
2. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
6. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
7. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
8. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
9. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
10. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
11. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2008)...der with Strong Clinical Research Relationships an...ations to Lead Commercialization, SANTA CLARA, Ca... Inc.,(OTC Bulletin Board: NWCI) a cardiac diagno...ncent W. Renz has joined NewCardio as its presiden...zation effort, to include,business development, cl...
(Date:8/17/2008)...tralia, Aug. 17 /Xinhua-- P...that the first pivotal Phase 3,clinical trial of B...,completed enrolment., The first efficacy data fr...e first half of 2009. The trial commenced its dosi...tment target of 250 subjects in June,2008 and clos...
(Date:8/14/2008)...A Complimentary Continuing Education Activity, VO...rus (CMV) is a,significant cause of morbidity and ... transplantation. The clinical manifestations of C...inal disease to life-threatening,pneumonia, myelos...r to prevent CMV infection and reduce CMV drug res...
(Date:8/14/2008)...EACH, Fla., Aug. 14 /- The Clinical T...ed at educating physicians,clinical coordinators,...,clinical trial. It will be held in Boca Raton at ...investigators, clinical coordinators, monitors and... about how to incorporate,clinical trials into a p...
Breaking Medicine Technology:Vincent W. Renz Joins NewCardio as President 2Vincent W. Renz Joins NewCardio as President 3Vincent W. Renz Joins NewCardio as President 4Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2CMV Disease in Stem Cell Transplantation: Prevention and Drug Resistance 2Previously Disclosed Changes in Board Composition of NightHawk Radiology Holdings Inc Prompt Notice of Noncompliance from the Nasdaq Global Market 14205 1Previously Disclosed Changes in Board Composition of NightHawk Radiology Holdings Inc Prompt Notice of Noncompliance from the Nasdaq Global Market 14205 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 1WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 4WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 5WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 6WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 7WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 8WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 9WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 10WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 11WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 12Cardiac Science to Present at the Seventh Annual Invest Northwest Conference 14201 1Cardiac Science to Present at the Seventh Annual Invest Northwest Conference 14201 2deCODE Genetics Announces Full year 2007 Financial Results 3913 1deCODE Genetics Announces Full year 2007 Financial Results 3913 2deCODE Genetics Announces Full year 2007 Financial Results 3913 3deCODE Genetics Announces Full year 2007 Financial Results 3913 4deCODE Genetics Announces Full year 2007 Financial Results 3913 5deCODE Genetics Announces Full year 2007 Financial Results 3913 6deCODE Genetics Announces Full year 2007 Financial Results 3913 7deCODE Genetics Announces Full year 2007 Financial Results 3913 8deCODE Genetics Announces Full year 2007 Financial Results 3913 9
...rCare offers five questions to help women,learn ab...June 12, 2007 – According to a new,GfK Roper...national,nonprofit cancer support organization, wh...id they know at least a fair amount,about breast c...,progress made in treatment. Fewer than one out of...
..., June 13, 2007--Three new drugs for,rheumatoid ar...t,for this difficult and debilitating condition. T... published early Online and in an,upcoming edition...onic,inflammatory joint diseases, affecting 0&midd...sed world. Its typical symptoms are,joint pain, st...
Other Medicine Technology:Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 2Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 3Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment 2Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment 3
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...n C such as papaya, oranges and blackcurrant may b... that the nutrient could help reduce some of the c... from the University of Warwick have found that th...up' free radicals that are produced in excess in d...
...ect has revealed that one-third of US teenagers wh...lying. It was found during the study that teen...e information on the Internet as compared to direc... also revealed that girls were more likely than bo...
...ws that CANCER death rates for men from the rural ...Despite The fact that cancer survival rates are im...ences between the recovery and death rate of men l...d their urban counterpart. The number of people di...
...buse and Alcoholism (NIAAA), a part of the U.S. Na...five distinct subtypes of alcoholism by analysing...lcohol dependence. Our findings should help dispe...alcoholic, notes first author Dr. Howard B. Moss, ...
Other Medicine News:Health News:One-third of US Teen Netizens are Victims of Cyber-bullying 2Health News:Cancer Deaths of Rural Men on the High 2Health News:Researchers Identify Five Distinct Subtypes of Alcoholism 2Health News:Researchers Identify Five Distinct Subtypes of Alcoholism 3
The DELFIA Platewash is a general purpose microtitration plate and strip washer especially standardized for use with DELFIA diagnostic kits.
SkanWasher 300 with a 25-microplate capacity stacker system. Vacuum pressure and aspiration and dispense probe heights are adjustable. On-board software for user to configure 8 different programs. Ex
...The Labcyte miniGene LW is a new plate washing sys... 96 and 384 channel microplates with flat, V-shape... with 8 or 16 channel nozzle heads. Simple LCD tou...tional plate stacker is available for the miniGene...
...Produce Up to 8000 L/day of Type III Laboratory-gr...ed to produce up to 8000 L/day of Type III laborat...omplete Purification and Control Unit, RiOs system...viding total control of all parameters within the ...
Medicine Products: